Free Trial
→ No. 1 stock to cash in on the death of iPhone (From Stansberry Research) (Ad)tc pixel
NASDAQ:IPSC

Century Therapeutics Q1 2025 Earnings Results & Report

Century Therapeutics logo
$1.47 +0.01 (+0.68%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$1.40 -0.07 (-4.76%)
As of 10/9/2026 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Century Therapeutics beat analyst expectations on both earnings and revenue in its Q1 2025 results, released May 15, 2025. The company reported EPS of $0.89 versus the -$0.31 consensus estimate, while revenue of $109.16 million topped the $45.52 million estimate by $63.64 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
9:30 AM ET

Century Therapeutics EPS Results

Actual EPS
$0.89
Consensus EPS
-$0.31
Beat/Miss
Beat by +$1.20
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Century Therapeutics Revenue Results

Actual Revenue
$109.16 million
Expected Revenue
$45.52 million
Beat/Miss
Beat by +$63.64 million
YoY Revenue Growth
N/A

Upcoming Earnings

Century Therapeutics' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 9, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Century Therapeutics' Q1 2025 Press ReleasePress Release
(8-K)
Century Therapeutics' Q1 2025 Quarterly reportQuarterly report
(10-Q)

Century Therapeutics Q1 2025 Earnings FAQ

Century Therapeutics (NASDAQ:IPSC) reported earnings of $0.89 per share for Q1 2025, beating the consensus estimate of -$0.31. The report was announced on Thursday, May 15, 2025.

Century Therapeutics reported revenue of $109.16 million for Q1 2025, against a consensus estimate of $45.52 million.

Century Therapeutics' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Century Therapeutics on the company's earnings history page.

Century Therapeutics Earnings Headlines

Century Therapeutics CNTY-813 Demonstrates Continued Advancement toward the Clinic Via Nonclinical Data Presented at EASD 2026
October 5, 2026  |  marketscreener.comM
Burning Rock Biotech (NASDAQ:BNR) versus Century Therapeutics (NASDAQ:IPSC) Head-To-Head Contrast
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31085546
No. 1 stock to cash in on the death of iPhone
Analyst Josh Baylin, who warned Congress about smartphones years before the iPhone launched, says the world's richest man may be building an iPhone rival he calls Starphone. Baylin points to FCC rulings, two trademarks filed the same day, multibillion-dollar spectrum deals, chip partnerships, and a string of posts from Elon Musk as evidence pointing to one conclusion. See the full research and the stock Baylin is watching now.tc pixel
October 10 at 1:00 AM  |  Stansberry Research (Ad)
Century Therapeutics, Inc. (NASDAQ: IPSC) Adds Two CNTY-813 Batches
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31085329
BioStem Technologies (OTCMKTS:BSEM) vs. Century Therapeutics (NASDAQ:IPSC) Critical Comparison
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31084783
Century Therapeutics, Inc. Presents Nonclinical Data For CNTY-813 At EASD
October 3, 2026  |  marketscreener.comM
See More Century Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Century Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Century Therapeutics and other key companies, straight to your email.

About Century Therapeutics

Century Therapeutics (NASDAQ:IPSC) (NASDAQ:IPSC) is a biotechnology company developing allogeneic cell therapies for cancer. The company uses induced pluripotent stem cell (iPSC) technology to create potentially scalable immune-cell products designed to treat patients without relying on cells collected from each individual patient.

Century’s research focuses primarily on iPSC-derived natural killer (NK) cells and T cells that are genetically engineered to recognize and attack cancer cells. Its pipeline has included investigational chimeric antigen receptor (CAR) cell therapies targeting blood cancers, including B-cell malignancies, with the goal of providing readily available, “off-the-shelf” treatments.

Founded in 2018 and headquartered in Philadelphia, Pennsylvania, Century Therapeutics conducts research and development activities in the United States. Its therapies remain investigational and are subject to clinical testing and regulatory review before they can be broadly marketed.

View Century Therapeutics Profile
Earnings Tools